Fox Chase Cancer Center and Temple Health Present Research at ...

PHILADELPHIA (May 31, 2024) — Fox Chase Cancer Center and Temple Health researchers will participate in the presentation and discussion of six research projects and two other speaking engagements at the 2024 American Society of Clinical Oncology Annual Meeting, which is being held May 31-June 4 in Chicago. 

Posters and Abstracts 

June 2 

Title: Utility of Axillary Surgery in Patients with De Novo Metastatic Breast Cancer Undergoing Surgery of the Primary Site. Date: June 2, 2024; 9:00 AM CDT Location: Hall A Abstract 1086, Poster Board 64 Presenter: Mahtab Vasigh, MD, Fox Chase Cancer Center 

Title: Does Sidedness Predict Risk of Perforation with Chemotherapy in Colon Cancer? Results from the National Inpatient Samples Database (NISD). Date: June 2, 2024; 4:30 PM CDT Location: Hall D2 Abstract e15591 Presenter: Jasmeet Kaur, MD, Fox Chase Cancer Center 

June 3 

Title: A Longitudinal, Palliative Care Educational Pilot in Hematology-Oncology Fellowship Training. Date: June 3, 2024; 9:45 AM CDT Location: E450a Abstract 9007 Presenter: Jessica R Bauman, MD, Fox Chase Cancer Center 

Title: Characterization of HER2 Alterations in Lung Adenocarcinoma. Date: June 3, 2024; 1:30 PM CDT Location: Hall A Abstract 8534, Poster Board 398 Presenter: Nikita Dahake, MD, Temple University Hospital 

Title: Tazemetostat in Combination with Topotecan and Pembrolizumab in Patients with Recurrent Small Cell Lung Cancer. Date: June 3, 2024 1:30 PM CDT Location: Hall A Abstract TPS8130, Poster Board 384b Presenter: Parth Anil Desai, MD, MBBS, Fox Chase Cancer Center

 June 4 

Title: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment-Naïve Metastatic Pancreatic Cancer (GIANT): ECOG-ACRIN EA2186. Date: June 4, 2024; 10:45 AM CDT Location: Hall D1 Abstract 4003 Presenter: Efrat Dotan, MD, Fox Chase Cancer Center 

Other Speaking Engagements/Publications 

May 31 

Title: Optimal Treatment Intensity for Frontline Therapy for Advanced Urothelial Cancer: Which Regimen for Which Patient? Date: May 31, 2024; 1:00 PM CDT Location: E450a Presenter: Pooja Ghatalia, MD, Fox Chase Cancer Center 

Title: The Value of Blinded Independent Central Review (BICR) in Recent Trials in Non-Small Cell Lung Cancer (NSCLC). Publication Only: Journal of Clinical Oncology 42, 2024 (suppl 16; abstract e23000) Martin J. Edelman, MD, FACP, Fox Chase Cancer Center